Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib and Obinutuzumab in Previously Untreated CLL
NCT02315768Phase 2Completed
- Sponsor
- University of California, San Diego
- Start
- Aug 2015
- Primary completion
- Apr 2022
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of ibrutinib, obinutuzumab in chronic lymphocytic leukemia (CLL), sponsored by University of California, San Diego. Started Aug 2015; status: completed.
02
Drugs
ibrutinibobinutuzumab
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT02315768.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02315768.